This article is more than 5 years old. Information may no longer be current.
Vexim launches new bone fixation biomaterial
Click Here to Manage Email Alerts
Vexim announced the launch of Interface cement, an innovative new biomaterial for bone fixation which is a biological alternative to existing orthopedic cements for treating traumatic vertebral fractures in patients with good bone quality.
The Interface product is used with Vexim’s SpineJack implant to preserve the existing bone tissue.
According to a company press release, the injection of the Interface biomaterial permits optimal stabilization of the vertebral body while facilitating bone remodeling. This osseointegration results from Interface’s specific formula, composed of 50% hydroxyapatite particles, with a formulation that is close to that of the structure of bone. Interface cement has a high viscosity, reduces the risk of leakage, and allows optimal working time before hardening, which makes it safer to inject. The cement also has high radiopacity, which allows precision monitoring as it is deployed in the vertebra.
“We are happy to provide surgeons with this new biomaterial, which improves the care of patients with traumatic bone fracture,” Vincent Gardes, chief executive officer of Vexim, stated in the release. “Its development builds on the mechanical qualities of our Cohesion cement, mainly designed for osteoporotic and tumor-related fractures, while improving osseointegration qualities, in order to target patients with high reossification potential, primarily young ones. In this way, we provide a range of advanced biomaterials, suitable for all types of vertebral compression fractures and sold in all our European markets,” he stated.